Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 139 for “"TNBC"”.
-
PRUNE_1 INVOLMENT IN TNBC ENHANCING CANCER METABOLISM
… demands. Triple-Negative Breast Cancer (TNBC), characterized by the absence of hormone and HER2 receptors, exhibits high glycolytic and oxidative phosphorylation (OXPHOS) activity, contributing to poor prognosis and metastasis. The ATP5A1 protein, a key component of mitochondrial ATP …
-
Development Of Recombinant Immunotherapeutics for Triple-Negative Breast Cancer (TNBC)
… cancers including Triple-negative breast cancer (TNBC), which is mainly characterized by a lack of expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). TNBC is one of the most aggressive subtypes of breast cancer, with a 20% …
-
Development of Rational Combination Therapy With Parp Inhibitors and Kinase Inhibitors In Tnbc
… cancers including triple negative breast cancer (TNBC). However, it has been reported that a subgroup of patients even with BRCA mutation fails to respond to PARPi in multiple clinical trials. In this study, we identified c-Met, a tyrosine kinase, phosphorylates PARP1 at Y907 and that the …
-
Localized and disease-selective drug delivery using adhesive hydrogels for treatment of locally advanced TNBC
Triple negative breast cancer (TNBC) is an aggressive form of cancer that represents 20% of invasive breast cancers, and about 15% are locally advanced at time of presentation. TNBC is negative for estrogen and progesterone receptor, as well as for HER2, and hence it is not treatable with common …
-
Mapping the spatial organisation of B cells and immune signalling in TNBC to characterise response to immunotherapy
… specifically in triple-negative breast cancer (TNBC) is poorly characterised. Organisation and function are processes that are likely orchestrated by diverse immune signalling, but what the interplay between organisation and its underlying signalling is, remains largely uncharacterised in …
-
The role of DNA damage associated microRNAs in enhancing the chemotherapeutic responses in triple negative breast cancer (TNBC)
Triple negative breast cancer (TNBC) is a heterogeneous aggressive type of mammary tumour which lacks a definite tailored therapeutic approach, consequently limiting treatment options to chemotherapeutic agents. Doxorubicin has demonstrated significant efficacy in the treatment of TNBC although …
-
Next-Generation version of pseudomonas exotoxin a based immunotoxins with reduced immunogenicity for triple negative breast cancer (TNBC) treatment
… in South Africa. Triple-negative breast cancer (TNBC) subtype, which is mainly characterized by a lack of expression of the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), patients do not benefit from current standard treatments since they …
-
Post-translationally Modified Glucocorticoid Receptors and Protein Tyrosine Kinase 6 Modulate Triple Negative Breast Cancer Phenotypes
Triple negative breast cancer (TNBC) is the most metastatic and deadly breast cancer subtype, accounting for 20-30% of all breast cancer cases. There is a critical need to identify molecular targets that could be exploited as new biomarkers of TNBC prognosis and for improving therapies. Although …
-
Clinical Relevance of the Immune Contexture and AXL Kinase in Triple-Negative Breast Cancer
Triple-negative breast cancers (TNBC) are usually associated with an aggressive phenotype, an increased risk of early relapse, and poor outcome. Burgeoning evidence demonstrates that TNBC encompasses distinct molecular entities that are differentially characterized by specific hallmarks of cancer, …
-
Sphingosine Kinase 1 Regulates Fascin Expression to Promote Metastasis In Triple Negative Breast Cancer
… still lacking. Triple negative breast cancer (TNBC) occurs in high frequency in young women and are more likely to recur and metastasize than are other breast cancer subtypes. Also, TNBC patients cannot benefit from currently available hormonal or targeted therapies, as they lack estrogen …
-
Synthetic Lethality of Cdk Inhibition and Doxorubicin In Triple-Negative Breast Cancer Requires P53 Inactivation
<p>Triple-negative breast cancer (TNBC) is an aggressive malignancy in which the tumors lack expression of estrogen receptor, progesterone receptor and HER2. As such, TNBC patients cannot benefit from clinically available targeted therapies and must rely on chemotherapy and surgery for treatment. …
-
Development of Targeted siRNA Therapeutics for Triple Negative Breast Cancer and Liver Fibrosis
… the treatment of triple negative breast cancer (TNBC) and liver fibrosis. siRNAs targeting vascular endothelial growth factor (VEGF) and IκB kinase ε (IKBKE) were used for treating TNBC, while siRNA targeting poly(rC) binding protein 2 (PCBP2) was used for treating liver fibrosis. In Chapter 1, …
-
Engineering multimodal nanoparticles to combat triple-negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive subtype of cancer that accounts for about 15-20% of all breast cancer cases and has a poorer short-term prognosis when compared to other subtypes. Many current chemotherapeutics used to treat TNBC are nonspecific, and, therefore, cause …
-
Preclinical Development of Therapeutic Strategies Against Triple-Negative and Inflammatory Breast Cancer
<p>Triple-negative (TNBC) and inflammatory (IBC) breast cancer are the most aggressive forms of breast cancer, accounting for 20% and 10% of cancer-related deaths, respectively. Among IBC cases, 30% are additionally classified with TNBC molecular pathology, a diagnosis that significantly worsens …
-
Identification of novel biomarkers and therapeutic strategies in triple negative breast cancer
Triple negative breast cancer (TNBC) is a highly heterogeneous disease that accounts for around 15% of all breast cancers but is responsible for a disproportionately high rate of mortality. Characterised by lack of expression of the hormone receptors estrogen receptor α (ERα), progesterone receptor …
-
Targeting Cox-2 and Rank In Aggressive Breast Cancers: Inflammatory Breast Cancer and Triple-Negative Breast Cancer
… cancer (IBC) and triple-negative breast cancer (TNBC) are two highly aggressive breast cancer subtypes associated with a poor outcome. Despite sensitivity to current treatment, these breast cancers subtypes have a high recurrence rate and proclivity to metastasize early. The aggressiveness of IBC …
-
Targeting Cox-2 and Rank In Aggressive Breast Cancers: Inflammatory Breast Cancer and Triple-Negative Breast Cancer
… cancer (IBC) and triple-negative breast cancer (TNBC) are two highly aggressive breast cancer subtypes associated with a poor outcome. Despite sensitivity to current treatment, these breast cancers subtypes have a high recurrence rate and proclivity to metastasize early. The aggressiveness of IBC …
-
SIK2 Inhibitor GRN-300 Enhances Sensitivity to Paclitaxel Treatment in Triple-Negative Breast Cancer
… 15% classified as Triple-Negative Breast Cancer (TNBC). TNBC lacks expression of estrogen (ER) and progesterone (PR), and does not overexpress HER-2, leaving patients without effective targeted therapies. As a result, treatment primarily relies on chemotherapy, most commonly paclitaxel, a taxane …
-
Combinatorial therapy for triple negative breast cancer and the effect of nanoscale surfaces
Triple negative breast cancer (TNBC) is a highly aggressive type of breast cancer with urgent clinical need for effective therapies. Resistance to standard clinical therapies with metastatic TNBC pushed the researchers to explore combinatorial therapy regime. A combination of STAT-3 specific …
-
Evaluating Phosphatidylinositide as Lipid Biomarkers for Hyperglycemia-related Triple-negative Breast Cancer Aggressiveness
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, marked by limited treatment options and poor patient outcomes. Clinical and epidemiological studies suggest that systemic metabolic conditions, particularly high blood glucose associated with Type 2 Diabetes, may …
Page 1 of 7